Introduction {#sec0001}
============

Optimization of drug use by older adults remains a priority. Recognition of this need has led to creation of explicit measures that suggest optimal medication practices for older adults, including the Beers' Criteria list[@bib0001] and Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) criteria.[@bib0002] Similarly, the Choosing Wisely initiative[@bib0003] works to promote changes in health care to avoid unnecessary tests, treatments, and procedures for patients. These quality indicators help clinicians and health system managers identify situations where risks from specific medications and procedures may outweigh benefits. Antipsychotic drugs are included among these explicit measures[@bib0001], [@bib0002], [@bib0003] as potentially inappropriate medications.

The high use of antipsychotic drugs by older adults is a concern due to their known increased risk of adverse drug events,[@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0008] which include akathisia,[@bib0009] movement disorders,[@bib0010] confusion,[@bib0011], [@bib0012] pneumonia,[@bib0013] falls,[@bib0014] cardiovascular effects (eg, hypertension, dyslipidemia, and obesity),[@bib0015] hypothyroidism,[@bib0016], [@bib0017], [@bib0018] neuroleptic malignant syndrome,[@bib0019] and death.[@bib0019], [@bib0020] In 2005, the US Food and Drug Administration (FDA) and Health Canada issued black box warnings regarding the increased risk of mortality in older adults with dementia treated with second-generation antipsychotic drugs.[@bib0004], [@bib0021], [@bib0022], [@bib0023] In response to observational studies that identified this risk, with the use of both typical and atypical antipsychotic drugs,[@bib0019], [@bib0020]^,^[@bib0023] the FDA extended this black box warning to include all antipsychotic drugs in 2008.[@bib0022], [@bib0024] As a result, antipsychotic agents are only recommended for use in those with a psychotic disorder or symptoms of dementia that have not responded to nonpharmacologic treatment.[@bib0025], [@bib0026], [@bib0027], [@bib0028], [@bib0029], [@bib0030] Despite existing quality indicators and limited indications approved by drug regulatory bodies, antipsychotic agents continue to be used off-label.[@bib0004], [@bib0008]^,^[@bib0031], [@bib0032], [@bib0033] Many times, off-label antipsychotic drug use occurs where precautions exist due to concomitant health issues (eg, Parkinsonism or history of falls), or where drug interactions exist (eg, augmented anticholinergic burden resulting in dry mouth or blurred vision.[@bib0004] Sensitivity to antipsychotic agent adverse effects in older adults is potentially related to age-related changes in the brain\'s response to these agents,[@bib0034] changes in the blood-brain barrier,[@bib0035], [@bib0036] and/or changes in drug metabolism and elimination.[@bib0037], [@bib0038]

We were interested in antipsychotic agent prescribing to older adults in Nova Scotia, Canada. We also wanted to explore concordance with the STOPP criteria that recommends antipsychotic drugs be avoided in those at risk of falls. We conducted a retrospective observational study using Nova Scotia administrative health data to identify annual trends in the dispensation of antipsychotic drugs to older persons (Objective 1). Additionally, with a continuous 4-year cohort, we identified the postdischarge continued dispensation of antipsychotic drugs in older persons who had experienced a fall-related hospitalization (Objective 2).

Methods {#sec0002}
=======

Sources of data {#sec0003}
---------------

### Nova Scotia Seniors' Pharmacare Program Database {#sec0004}

The Nova Scotia Seniors' Pharmacare Program Database (NSSPP) is a provincial drug insurance plan for eligible residents of Nova Scotia, aged 65 years and older qualifying for provincial health coverage (<https://novascotia.ca/dhw/pharmacare/seniors-pharmacare.asp>). This database was used to identify older adults aged 66 and older for Objectives 1 and 2 in separate data extractions: Objective 1 is based on annual cohorts, whereas Objective 2 has a 4-year single cohort.

Nova Scotians may choose to enroll in this provincially funded drug plan at age 65 years. Opting in requires registration and payment of an annual premium and a copayment, both with an annual maximum (exceptions exist for low-income seniors).[@bib0039] The NSSPP provides benefits for approximately 66% of this older population.[@bib0040] Approximately 92% of NSSPP beneficiaries live in the community; 8% live in a variety of care-based settings long-term care facilities). Nova Scotians are excluded from the NSSPP if they receive benefits from a federal government drug insurance program (eg, Veterans Affairs Canada or Non-Insured Health Benefits for First Nations People and Inuit), Nova Scotia Family Pharmacare, or any private plan that covers most medications and supplies. Nova Scotians who qualify for NSSPP but choose to pay for prescriptions themselves are not included in the NSSPP database.

The NSSPP database records prescriptions dispensed in community pharmacies to program beneficiaries who are living in the community or long-term care facilities. Prescription claims data from the NSSPP include demographic details (eg, age and sex) and information on prescriptions dispensed, including the generic and brand name of the medication, strength, quantity, days supplied, and cost. NSSPP data do not contain medications administered in hospitals, on discharge, or in emergency departments.

### World Health Organization Anatomical Therapeutic Chemical Classification System codes {#sec0005}

Antipsychotic drugs were identified by 2015 World Health Organization Anatomical Therapeutic Chemical Classification System **(**codes for data extraction for both Objectives 1 and 2 (<https://www.whocc.no/atc_ddd_index/>) ([Appendix 1](#sec0020){ref-type="sec"}).

### Canadian Institute of Health Information Discharge Abstract Database {#sec0006}

The Canadian Institute of Health Information Discharge Abstract Database (DAD) records acute patient discharge information from 33 acute care facilities in Nova Scotia (<https://www.cihi.ca/en/discharge-abstract-database-metadata>). The DAD was used for Objective 2.

Participants {#sec0007}
------------

### Trends in antipsychotic dispensations (Objective 1) {#sec0008}

NSSPP claims data were used to determine the annual prevalence, sex, and age categories of NSSPP beneficiaries aged 66 years and older who received at least 1 dispensation of an antipsychotic drug during a fiscal year between April 1, 2009, and March 31, 2014. Each year, the cohort differs as beneficiaries aged, moved, died, or opted in or out of the program.

### Antipsychotic dispensations before and following fall-related hospitalization (Objective 2) {#sec0009}

Our second objective was to explore concordance with the STOPP criteria that recommends antipsychotic drugs be avoided in older adults at risk of falls.[@bib0002] NSSPP claims and DAD data were linked to determine unique NSSPP beneficiaries aged 66 years and older with a fall-related hospitalization 100 days following dispensation of an antipsychotic drug between April 1, 2009, and March 31, 2013. These individuals are at a high risk of falls because a previous fall is among the greatest predictors for future falls.[@bib0041], [@bib0042], [@bib0043] Although our study period began April 1, 2009, a 100-day window was required at the beginning to identify antipsychotic drug dispensations. Our first fall-related hospitalization was included after May 13, 2009. This design was chosen to provide proximity between the drug supply and the date of the fall, establishing the possible contribution (ie, biologic plausibility) of the antipsychotic drug to the fall-related hospitalization. The choice of a 100-day period reflects the NSSPP usual reimbursement of up to a 100-day drug supply, and would suggest that a patient would still have had access to the antipsychotic drug.

Design {#sec0010}
------

The NSSPP database, the DAD, and Nova Scotia vital statistics for deaths are housed at Dalhousie\'s Health Data Nova Scotia data repository (<https://medicine.dal.ca/departments/department-sites/community-health/research/hdns/health-databases.html>). Linkage occurred using unique de-identified and encrypted identifiers based on a patient\'s Medical Services Insurance number. Following data linkage by Health Data Nova Scotia, person-specific, anonymized, and categorized results were supplied to the study statistician (KM). Length-of-stay and disposition (discharge or death) were identified for the fall-related hospitalizations. As well, surviving patients who received an antipsychotic drug dispensation during the 100 days following discharge from hospital were identified. We did not capture the number of patients with multiple fall-related hospitalizations in each fiscal year; only the first fall-related hospitalization was evaluated.

Statistical analysis {#sec0011}
--------------------

For Objective 1, descriptive statistics were performed to summarize population characteristics (sex and age categories) of NSSPP beneficiaries who received at least 1 antipsychotic drug dispensation in a fiscal year, and the types (atypical vs typical) and generic name of the antipsychotic drug dispensed. We reported counts and frequencies for categorical and continuous variables. Annual trends in antipsychotic drug dispensations were analyzed using the Cochrane-Armitage trend test. Cochran-Armitage tests for trends in binomial proportions across levels of either a single factor or a covariate and can detect trends in data that are not ideal for more traditional statistical tests.[@bib0044] Logistic regression models were used to model the risk of potentially inappropriate therapy (ie, antipsychotic drugs dispensed to older adults with an increased risk of falls) and covariates identified a priori: year of admission, sex, length of stay, days supply, and age category. All variables were entered into a multivariate model where adjusted odds ratios and 95% CIs were reported. Significance was accepted as a *P* value \< 0.05. All statistical analysis was completed using SAS version 9.3 (SAS Institute Inc, Cary, North Carolina).

This research received ethics approval from the Health Sciences Research Ethics Board, Dalhousie University, Halifax, Nova Scotia (\#2014-3302), with subsequent renewals. Approval for the research study, including data linkage, was obtained from the Health Data Nova Scotia Data Access Committee.

Results {#sec0012}
=======

Trends in antipsychotic dispensations (Objective 1) {#sec0013}
---------------------------------------------------

We identified that in each year observed approximately 6% of eligible NSSPP beneficiaries received at least 1 antipsychotic drug dispensation. Of approximately 6000 persons in each year\'s cohort, the proportion of women varied from 65% (2013) to 67.5% (2009). [Figure 1](#fig0001){ref-type="fig"} and [Figure 2](#fig0002){ref-type="fig"} show the cohort categorized by age and sex (further details in [Appendix 2](#sec0021){ref-type="sec"}).Fig. 1Percent of eligible male Nova Scotia Seniors' Pharmacare Program beneficiaries receiving at least 1 antipsychotic drug dispensation per year, by age category and fiscal year (April 1, 2009--March 31, 2014).Fig 1Fig. 2Percent of eligible female Nova Scotia Seniors' Pharmacare Program beneficiaries receiving at least 1 antipsychotic drug dispensation per year, by age category and fiscal year (April 1, 2009--March 31, 2014).Fig 2

[Table 1](#tbl0001){ref-type="table"} shows the antipsychotic dispensations made to our total cohort by generic drug name. Second-generation antipsychotic drugs---risperidone and quetiapine---made up more than 60% of the antipsychotic drug prescriptions dispensed.Table 1Individual antipsychotic drugs dispensed to eligible Nova Scotia Seniors' Pharmacare Program beneficiaries receiving at least 1 antipsychotic dispensation per year, by fiscal year (April 1, 2009--March 31, 2014).[\*](#tb1fn1){ref-type="table-fn"}Table 1Antipsychotic drugs dispensed20092010201120122013First generationChlorpromazine137 (2.3)130 (2.2)120 (2.0)116 (1.9)109 (1.8)Flupentixol28 (0.5)30 (0.5)37 (0.6)35 (0.6)38 (0.6)Fluphenazine26 (0.4)21 (0.4)22 (0.4)27 (0.5)22 (0.4)Haloperidol336 (5.7)412 (6.8)405 (6.7)450 (7.5)446 (7.4)Levomepromazine or methoprazine285 (4.8)259 (4.3)270 (4.5)254 (4.2)237 (4.0)Loxapine86 (1.5)81 (1.3)89 (1.5)84 (1.4)76 (1.3)Periciazine8 (0.1)6 (0.1)\< 5\< 5\< 5Perphenazine229 (3.9)218 (3.6)192 (3.2)177 (2.9)163 (2.7)Pimozide27 (0.5)29 (0.5)25 (0.4)25 (0.4)23 (0.4)Prochlorperazine530 (8.9)523 (8.7)460 (7.6)430 (7.1)380 (6.3)Tiotixene or Thiothixene\< 5\< 5\< 5\< 5\< 5Trifluoperazine112 (1.9)111 (1.8)99 (1.6)89 (1.5)108 (1.8)Zuclopenthixol\< 5\< 5\< 5\< 56Subtotal∼1804 (∼30.3)∼1820 (∼30.2)∼1719 (∼28.5)∼1687 (∼28.0)∼1608 (∼26.7)  Second generationAripiprazole\< 5\< 5\< 514 (0.2)27 (0.5)Clozapine7 (0.1)11 (0.2)14 (0.23)15 (0.3)19 (0.3)Olanzapine443 (7.5)453 (7.5)458 (7.6)459 (7.6)447 (7.5)Quetiapine1780 (29.9)2003 (33.1)2212 (36.6)2308 (38.2)2380 (39.6)Risperidone1910 (32.1)1753 (29.0)1626 (26.9)1538 (25.5)1519 (25.3)Ziprasidone\< 5\< 5\< 5\< 5\< 5Subtotal∼4140 (∼69.6)∼4220 (∼69.8)∼4310 (∼71.3)4334 (∼71.8)∼4392 (∼73.2)  Total59466044604060296004[^1]

### Antipsychotic drug dispensations before and following fall-related hospitalization (Objective 2) {#sec0014}

There were 585 eligible NSSPP beneficiaries who received at least 1 antipsychotic drug dispensation during the 100 days before a fall-related hospital admission between May 13, 2009, and March 31, 2013 ([Figure 3](#fig0003){ref-type="fig"}). Of these, 62 (10.6%) died in hospital. Of 523 surviving beneficiaries, the majority--- 400 (76.5%)---had an antipsychotic drug dispensation within 100 days of discharge. The age and sex breakdown of the NSSPP beneficiaries who survived a fall-related hospitalization that was preceded by at least 1 antipsychotic drug dispensation in the 100 days prior is shown in [Table 2](#tbl0002){ref-type="table"}. [Table 3](#tbl0003){ref-type="table"} shows the distribution of individual antipsychotic drugs dispensed before and after a fall-related hospitalization.Fig. 3Cohort for Objective 2 (post discharge continued dispensation of antipsychotic drugs in older persons who had experienced a fall-related hospitalization). NSSPP = Nova Scotia Seniors' Pharmacare Program. \*Only data from NSSPP; older adults may have received prescriptions from other sources such as private insurance.Fig 3Table 2Age category and sex of eligible Nova Scotia Seniors' Pharmacare Program beneficiaries who experienced a fall-related hospitalization, after dispensation of an antipsychotic drug during the 100 days before the fall (April 1, 2009--March 31, 2013).[\*](#tb2fn1){ref-type="table-fn"}Table 2SexAge group, y[†](#tb2fn2){ref-type="table-fn"}Total66-6970-7475-7980-8485-8990+Female32 (64.0)42 (63.6)59 (67.1)81 (72.3)98 (85.2)86 (93.5)398Male18 (36.0)24 (36.4)29 (32.9)31 (27.7)17 (14.8)6 (6.5)125Total50668811211592523[^2][^3]Table 3Individual antipsychotic drugs dispensed to eligible Nova Scotia Seniors' Pharmacare Program beneficiaries before a fall-related hospitalization and following discharge (April 1, 2009--March 31, 2013).[\*](#tb3fn1){ref-type="table-fn"}Table 3Antipsychotic drug dispensedDuring 100 d before fall-related hospitalizationDuring 100 d following dischargeFirst generationChlorpromazine6 (1.2)6 (1.5)Haloperidol23 (4.4)14 (3.5)Levomepromazine or methoprazine12 (2.3)9 (2.3)Loxapine8 (1.5)8 (2.0)Perphenazine12 (2.3)8 (2.0)Prochlorperazine13 (2.5)\<5Subtotal74 (14.2)45 (11.3)  Second generationOlanzapine29 (5.5)28 (7)Quetiapine238 (45.5)195 (48.8)Risperidone172 (32.9)119 (29.8)Subtotal439 (83.9)342 (85.6)Flupentixol, pimozide, clozapine, Fluphenazine, periciazine, trifluperazine\
and prochloperazine after fall[†](#tb3fn2){ref-type="table-fn"}10 (1.9)13 (3.3)Total523400[^4][^5]

No significant predictors for the continuation of antipsychotic drugs following discharge were found. Both univariate and multivariate regression were performed to evaluate the potential predictive value of the fiscal year of admission, sex, length of stay in hospital, and age as predictors of discontinuation of the antipsychotic drug for NSSPP beneficiaries after experiencing a fall-related hospitalization within 100 days of an antipsychotic drug dispensation ([Appendix 3](#sec0022){ref-type="sec"}).

Discussion {#sec0015}
==========

Results from our analysis of annual trends in antipsychotic drug dispensations (Objective 1) showed that each year for 5 years from April 1, 2009, through March 31, 2014, approximately 6% of NSSPP beneficiaries were dispensed at least 1 antipsychotic drug prescription. The rate of dispensation did not vary significantly over the 5 years. Women and older adults were more likely to receive antipsychotic drug dispensations.

A study of community-dwelling adults aged 65 years and older living in the Canadian province of Manitoba showed lower antipsychotic dispensations than we found in our population; 1.35% and 0.59% received second and first-generation antipsychotic drugs, respectively.[@bib0045] Our data showed that 60% of antipsychotic drug dispensations were for risperidone and olanzapine and that approximately one-third were for first-generation antipsychotic drugs. Although our results are similar in the distribution between first- and second-generation antipsychotic drug dispensations, time frame, and design, the Manitoba study included residents of all ages and was also able to report separately for patients living in nursing homes versus the community.

In studies of older adults in Canada; Japan; Taiwan; Denmark; Finland; France; Germany; Lithuania; Italy; the Netherlands; Norway; Spain; Sweden; Australia; New Zealand; Colombia; and the United States rates of antipsychotic drug prescribing varied widely. Antipsychotic drug use was as low as 0.32% in Colombia and as high as 15% for Taiwanese older adults.[@bib0045], [@bib0046], [@bib0047], [@bib0048], [@bib0049], [@bib0050], [@bib0051], [@bib0052], [@bib0053] Some of the studies were in earlier time periods than our investigation; that is, before widespread knowledge of the risks of antipsychotic agents, especially for those with dementia.

The US Medical Expenditure Panel Survey of 2004-2005 (USMEPS) provides a useful description of the characteristics of antipsychotic drug users and a breakdown of the drugs used.[@bib0046] Based on the self-reported data samples (all age groups), the study estimated that approximately 1.3% of the US population uses antipsychotic drugs, and within this population risperidone (26%), quetiapine (25%), and olanzapine (20%) were the antipsychotic drugs used most frequently. The higher rates of quetiapine dispensations in our study (40% in 2013) may be related to the age of the surveyed individuals (only 13% were older than age 65 years in the USMEPS study), the older survey dates, and possibly to off-label potentially inappropriate use of quetiapine in our cohort for insomnia.[@bib0008], [@bib0054] Although the 10-year-old USMEPS study gave a much clearer description of the socioeconomic status and the race/ethnicity of its participants, it did not focus specifically on an older population and employed survey data subject to recall bias.

Kales et al,[@bib0055] using time-series methodology, found that in community-dwelling US veterans aged 65 years and older with dementia, quetiapine dispensation increased from 0.35% to 6.09% of all antipsychotic drug prescribing between 1999 and 2005. The greatest increase was before FDA post-black box warning period (2003-2005). There was very little decline in quetiapine use after the FDA black box warning in 2006-2007.[@bib0055] The authors hypothesized that the period of increase from 1999 to 2005 was related to Veteran\'s Affairs recommendation to use risperidone and quetiapine (vs other antipsychotics) for behavioral and psychological symptoms of dementia due to a lack of difference in efficacy, a lack of safety warnings for quetiapine, and cost savings.[@bib0055] They also note that quetiapine may have been prescribed in low doses as a sedative and hypnotic.[@bib0055] The leveling off of use, they proposed, was related to reluctance to prescribe or to alter seemingly successful therapy after the warnings were released. The strength of this study lies in its longitudinal design; however, it reflects the antipsychotic prescribing in a veteran population, consisting of mainly male patients with dementia diagnoses. Multiple warnings regarding mortality risk in persons with dementia taking antipsychotic drugs had been released before our first year of analysis (ie, 2009). As well, the most commonly used drugs (risperidone and quetiapine) were multisource drugs by the time of our study and were available as both generic and brand-name medications. Thus, we were unable to study the effect of the FDA and Health Canada warnings[@bib0021], [@bib0022], [@bib0024] or introduction of multisource drugs. In contrast to Kales et al,[@bib0055] our mixed-sex population that included both patients with and without a diagnosis of dementia, captured between 2009 and 2014 showed that quetiapine dispensations increased from representing 30% in 2009 of all antipsychotic drug dispensations to 40% in 2014.

In our study, antipsychotic drug dispensations exceeded expectations despite recommendations from guidelines to limit antipsychotic drug prescribing to appropriate indications.[@bib0002]^,^[@bib0025], [@bib0026], [@bib0027], [@bib0028], [@bib0029], [@bib0030] The Canadian Foundation for Healthcare Improvement describes expected antipsychotic use in nursing homes to be between 5% and 15%.[@bib0056] In our study, with a cohort in which the majority of patients were community-living, we found that there was an annual rate of 6% of older adults receiving at least 1 antipsychotic drug dispensation. We are especially concerned about the issue of off-label antipsychotic drug prescribing quantified by Equale et al,[@bib0054] who found that 43.8% of all antipsychotic agents (and 66.7% of quetiapine) were prescribed off-label. We were unable to establish evidence of off-label antipsychotic drug use due lack of access to medical information such as diagnosis.

Results from the linked antipsychotic dispensation and fall-related hospitalization data (Objective 2) demonstrate that 585 of NSSPP beneficiaries who were dispensed an antipsychotic drug experienced a fall-related hospitalization. Seventy-seven percent of survivors of a fall-related hospitalization (following the dispensation of an antipsychotic drug in the 100 days prior) received an antipsychotic in the 100 days postdischarge. This finding is distinctly discordant with the STOPP criteria that state that antipsychotic drugs are potentially inappropriate for older adults at risk of falling.[@bib0002] Those who have had a previous fall are at an increased risk of a future fall^41--43^ and attempts should be made to decrease antipsychotic drug use in this population.

There were more fall-related hospitalizations in women in our study population. In a report of older adult fallers in the Eastern Health region of Newfoundland,[@bib0057] the rate of women\'s fall-related hospitalization was twice that of men. The authors suggest that increased fall-related hospitalization in women may be partially explained by osteoporosis increasing women\'s potential for more serious injury. It is unclear if, in our cohort, antipsychotic drugs were overlooked as a contributor to falls or whether they were deemed crucial for patient management.

In 2014, approximately one-third of older adults in the United States reported falling.[@bib0053] One in 5 falls required medical attention, and fractures that occurred in 6% to 10% of falls result in hospitalization and may lead to functional decline, loss of independence, social withdrawal, fear, activity avoidance, and death.[@bib0058], [@bib0059], [@bib0060], [@bib0067] One of the fall prevention strategies is managing medications that are implicated as contributors to falls.[@bib0058] Antipsychotic drug use increases the risk of falls.[@bib0014], [@bib0059] Explicit criteria[@bib0001], [@bib0002] and systematic reviews[@bib0060], [@bib0061] advocate for a trial reduction in antipsychotic drug use and cessation if possible after a fall. The implementation of integrated care models in Nova Scotia whereby community and hospital pharmacy services collaborate with other health care professionals to adjust therapy and monitor for future adverse drug events would be useful.

Interventions are required to improve the quality of the prescribing of antipsychotic drugs in older adults at the patient, caregiver, prescriber, health care facility, and system levels. Some jurisdictions have been successful and others unsuccessful[@bib0062] with interventions to improve prescribing of antipsychotic agents. The following examples highlight some of the successes and failures. Between 2011 and 2014 in Sweden with the assistance of a pay-for-performance model for physicians, the number of antipsychotic drugs being prescribed with no clear indication in older adults aged 75 years and older was reduced by 12%.[@bib0063] Alternatively, a Canadian academic detailing study initiated in 2014 and based in Ontario Nursing Homes has published preliminary results showing insignificant changes in prescribing of antipsychotic drugs.[@bib0064] Improvements in processes may improve results as this study continues. In 2013, a Winnipeg long-term-care facility piloted a program to reduce antipsychotic drug prescribing to patients with dementia. Based on the success of their model and early results (27% of 70 dementia patients were de-prescribed antipsychotic drugs over a 6-month period with no negative influence on behavior), in 2014, the Canadian Foundation for Healthcare Improvement ([www.cfhi-fcass.ca](http://www.cfhi-fcass.ca){#interref0006}) became involved in assisting this project achieving a pan-Canadian scope. Currently, the Reducing Antipsychotic Medication Use in Long Term Care collaboration includes 56 facilities from Atlantic Canada to British Columbia. Between 2014 and 2016, Tasmanian long-term-care facility researchers engaged in an educational/audit and feedback intervention with the objective of reducing both antipsychotic drug and benzodiazepine prescribing. By the 6-month evaluation, the prevalence of residents regularly prescribed antipsychotic agents was reduced by 13% (from 21.6%).[@bib0065]

This study represents, to our knowledge, the first time that the continuation of an antipsychotic drug following a fall-related hospitalization has been assessed in Canada. Two previous Canadian studies (Winnipeg and Toronto) have examined the relationship between antipsychotic agents and fall risk at a population level but these studies failed to evaluate prescribing after the fall-related event.[@bib0066], [@bib0067] The study completed in nursing home residents in Winnipeg, Canada, used a case-control design to evaluate the risk of falls associated with use of atypical antipsychotic drugs and demonstrated that more than 150 mg/d quetiapine (odds ratio = 3.6; 95% CI, 1.3--10.2) or 2 mg/d risperidone (odds ratio = 3.1; 95% C, 1.2--7.9) was associated with an increased risk of falling. Olanzapine did not show an increased risk of falling at any dose.[@bib0066] A population-based cohort study in Ontario, Canada, suggested that a new outpatient prescription for an atypical antipsychotic medication was associated with a 52% increased risk of a serious fall and a 50% increased risk of a nonvertebral osteoporotic fracture[@bib0067] compared with those who did not initiate atypical antipsychotic therapy.

Strengths and limitations {#sec0016}
-------------------------

The choice of retrospective cross-sectional design for our observational study was cost-efficient and allowed us to use person-specific de-identified data at a provincial level. By linking the 2 comprehensive longitudinal databases (NSSPP and DAD databases), we were able to assess the continuation of antipsychotic drug dispensation following a fall-related hospitalization and implement a population wide subnational antipsychotic drug prescribing indicator.

Our heterogeneous population includes both rural and urban and both community and long-term care dwelling adults older than age 66 years with varying levels of socioeconomic status. We have accessed the antipsychotic drug dispensation records of older adults usually excluded from clinical trials. Participants were not excluded because of any diagnosis or care status.

Although the study only captures two-thirds of Nova Scotian older adults and may not be generalizable to all older Nova Scotians, a more comprehensive database (<https://novascotia.ca/dhw/ehealth/dis/>) available during the summer of 2018 offers the ability to establish the antipsychotic dispensations of all Nova Scotians.

We were unable to incorporate specific patient variables including indications for antipsychotic drug use, comorbidity, cognition, socioeconomic status, multiple morbidities, and severity of illness.[@bib0070] Patient variables that may have influenced fall risk such as visual impairment and living arrangements (eg, community, residential care facilities, or nursing home) were not available. Our databases did not offer data on genomic analysis or individual drug levels or pharmacokinetic variation. Two of our age categories reflect uneven year ranges, which may make it more challenging to draw conclusions or make comparisons to other age groups.

Our study was based on prescription dispensation data. We used World Health Organization Anatomical Therapeutic Chemical Classification System codes to access our drug data and not drug identification numbers; therefore, we did not record if generic or brand-name drugs were supplied. Because we did not have access to dosage data, we were unable to determine whether antipsychotic drug use was being tapered following the fall-related hospitalizations.

We were unable to detect whether prescription drugs were dispensed but not consumed by patients or whether patients were adherent to prescribed directions. We did not determine treatment adherence using such approaches as refill data. We were unable to determine whether participants were independent for medication management, were sharing medications, or had supported medication management and what the influence of this support would be on medication adherence. We were unable to collect data about medication sharing that may occur in populations of older adults.[@bib0068], [@bib0069] In a previous study that examined the influence of patient hospitalization on adherence determined by administrative data, it was noted that the effect was small at a population level because 70% of patients were never hospitalized and 17% were hospitalized ≤7 days.[@bib0070] Antipsychotic drugs dispensed during the 100 days before hospitalization may not have been consumed at the time of the fall. Concomitant drug use (both prescription and over the counter), single prescription versus chronic drug use, and nonoral antipsychotic agent use were not included in our research study. Because we did not follow individual patients over time and we did not have access to data relating to switches in antipsychotic medications.

Our fall injury information was restricted to fall-related hospitalizations. Falls that resulted in either no primary care visit or resulted in a visit to a physician\'s office or walk-in clinic have not been recorded. We did not examine data by characteristics of the prescriber or health care institution where they patients were hospitalized for a fall.

We did not complete a longitudinal analysis but instead made comparisons of repeated cross-sectional analyses. Future work could involve longitudinal data analysis using such approaches as marginal models or generalized estimating equations to better capture the changes in prescription drug use and disease processes over time.

Conclusions {#sec0017}
===========

In each of the five fiscal years of our study, approximately 6% of our cohort of Nova Scotian older adults were dispensed at least one antipsychotic with approximately 60% of prescriptions being for a second-generation antipsychotic. Women were dispensed more antipsychotics than men at all ages and had increasing antipsychotic dispensation with increasing age. In our cohort of beneficiaries experiencing a fall-related hospitalization following antipsychotic dispensation in the 100 days prior to the fall, 76.5% had an antipsychotic dispensation within 100 days of hospital discharge. There were no risk factors identified to predict continuation of an antipsychotic after a fall-related hospitalization. Future work should focus on interventions such as validated screening criteria incorporated into computer-assisted order-entry or health care surveillance systems such as medication review to facilitate a significant, manageable and sustainable improvement in falls prevention and patient care. Our study demonstrates that prescribing quality can be assessed on a population level and we look forward to continued evaluation of prescribing in our province, nationally and internationally.

Appendix 1 {#sec0020}
==========

Antipsychotic drugs (N05A) dispensed to adults aged 66 years and older enrolled in the Nova Scotia Seniors' Pharmacare Program between April 1, 2009, and March 31, 2014, included aripiprazole, chlorpromazine, clozapine, flupentixol, fluphenazine, haloperidol, levomepromazine or methoprazine, loxapine, olanzapine, periciazine, perphenazine, pimozide, prochlorperazine, quetiapine, risperidone, tiotixene or thiothixene, trifluoperazine, ziprasidone, and zuclopenthixol. Note that lithium is not included in this list.

Appendix 2 {#sec0021}
==========

Percent of eligible Nova Scotia Seniors' Pharmacare Program beneficiaries receiving at least 1 antipsychotic drug dispensation per year, by sex, age category, and fiscal year (April 1, 2009--March 31, 2014).Age20092010201120122013FemalesMalesFemalesMalesFemalesMalesFemalesMalesFemalesMales66-693.963.754.043.843.943.853.883.773.923.8370-744.804.454.734.294.604.374.464.304.254.1875-796.035.965.985.665.785.465.785.235.535.0580-848.126.408.016.968.186.908.066.547.486.1185-8910.708.7510.999.4510.868.559.908.579.618.6390+15.6811.7015.519.9115.0510.5315.0411.2814.6211.90

Appendix 3 {#sec0022}
==========

Multivariate model estimates for risk of receiving inappropriate therapy within 100 days after a fall with risk factors in eligible Nova Scotia Seniors' Pharmacare Program beneficiaries receiving at least 1 antipsychotic drug dispensation per year, by sex, age category, and fiscal year (April 1, 2009--March 31, 2013).[\*](#utb1fn1){ref-type="table-fn"}VariableOdds ratio95% CI*P* valueFiscal year of admission0.9940.821--1.2030.9470Gender (female vs male)1.5410.945--2.5120.0829Length of stay per 30-d increase  0.9580.8591--1.0680.4421Days supply30 to \<60 vs \<301.2080.779--1.8750.773160 to \<90 vs \<301.0730.418--2.75590+ vs \<301.4830.567--3.877  Age class, y70-74 vs 66-690.9640.964--2.2970.088175-79 vs 66-691.3690.580--3.22680-84 vs 66-691.4450.631--3.30885-89 vs 66-690.7100.324--1.55790+ vs 66-690.6000.266--1.352[^6]
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[^1]: Values are presented as n (%).

[^2]: Cochran-Armitage trend test *P* \< 0.0001.

[^3]: Values are presented as n (%).

[^4]: Values are presented as n (%).

[^5]: Grouped because each were dispensed \<5 times during the study period.

[^6]: Modeled as the odds of receiving inappropriate therapy within 100 days after a fall.
